Drug Information
Drug (ID: DG00385) and It's Reported Resistant Information
Name |
Piperacillin/Tazobactam
|
||||
---|---|---|---|---|---|
Synonyms |
Tazocin (TN); Zosyn (TN); Piperacillin-tazobactam; Piperacillin-tazobactam mixt.; Piperacillin-tazobactam mixture; NIOSH/XI0191450; Piperacillin sodium and tazobactam; DTXSID001016418; Tazobactam and piperacillin (JP17); Piperacillin-tazobactam mixt. (4:1); Tazobactam-piperacillin mixt. (1:4); XI01914500; D02505; 4-Thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 3-methyl-7-oxo-3-(1H-1,2,3-triazol-1-ylmethyl)-, 4,4-dioxide, (2S-(2-alpha,3-beta,5-alpha))-, mixt. with (2S-(2-alpha,5-alpha,6-beta(S*)))-6-(((((4-ethyl-2,3-dioxo-1-piperazinyl)carbonyl)amino)phenylacetyl)amino)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid (1:4)
Click to Show/Hide
|
||||
Structure | |||||
Drug Resistance Disease(s) |
Disease(s) with Clinically Reported Resistance for This Drug
(6 diseases)
Bacterial infection [ICD-11: 1A00-1C4Z]
[1]
Malaria [ICD-11: 1F45]
[2]
Peritonitis [ICD-11: DC50]
[3]
Pneumonia [ICD-11: CA40]
[4]
Sclerosing cholangitis [ICD-11: DB96]
[5]
Ulcer [ICD-11: EH90]
[6]
|
||||
Click to Show/Hide the Molecular Information and External Link(s) of This Drug | |||||
Formula |
C33H38N9NaO12S2
|
||||
IsoSMILES |
CCN1CCN(C(=O)C1=O)C(=O)N[C@@H](C2=CC=CC=C2)C(=O)N[C@H]3[C@@H]4N(C3=O)[C@H](C(S4)(C)C)C(=O)[O-].C[C@@]1([C@@H](N2[C@H](S1(=O)=O)CC2=O)C(=O)O)CN3C=CN=N3.[Na+]
|
||||
InChI |
1S/C23H27N5O7S.C10H12N4O5S.Na/c1-4-26-10-11-27(19(32)18(26)31)22(35)25-13(12-8-6-5-7-9-12)16(29)24-14-17(30)28-15(21(33)34)23(2,3)36-20(14)28;1-10(5-13-3-2-11-12-13)8(9(16)17)14-6(15)4-7(14)20(10,18)19;/h5-9,13-15,20H,4,10-11H2,1-3H3,(H,24,29)(H,25,35)(H,33,34);2-3,7-8H,4-5H2,1H3,(H,16,17);/q;;+1/p-1/t13-,14+,15-,20+;7-,8+,10+;/m01./s1
|
||||
InChIKey |
TUPFOYXHAYOHIB-WZGOVNIISA-M
|
||||
PubChem CID |
Type(s) of Resistant Mechanism of This Drug
DISM: Drug Inactivation by Structure Modification
Drug Resistance Data Categorized by Their Corresponding Diseases
ICD-01: Infectious/parasitic diseases
Bacterial infection [ICD-11: 1A00-1C4Z]
Drug Resistance Data Categorized by Their Corresponding Mechanisms | ||||
Drug Inactivation by Structure Modification (DISM) | ||||
Key Molecule: Beta-lactamase (BLA) | [1] | |||
Molecule Alteration | Missense mutation | p.Y104A+p.N110D+p.E175Q+p.S179A |
||
Resistant Disease | Bacterial infection [ICD-11: 1A00-1C4Z] | |||
Experimental Note | Identified from the Human Clinical Data | |||
In Vitro Model | Escherichia coli TOP10 | 83333 | ||
Acinetobacter baumannii CIP70.10 | 470 | |||
Klebsiella pneumoniae kP3 | 1290996 | |||
Pseudomonas aeruginosa PU21 | 287 | |||
Experiment for Molecule Alteration |
Whole genome sequence assay; Allelic frequency measurement assay | |||
Experiment for Drug Resistance |
MIC assay | |||
Mechanism Description | K. pneumoniae kP3 was resistant to all Beta-lactams, including carbapenems, and expressed the carbapenem-hydrolyzing Beta-lactamase OXA-181, which differs from OXA-48 by four amino acid substitutions. Compared to OXA-48, OXA-181 possessed a very similar hydrolytic profile. | |||
Key Molecule: Beta-lactamase (BLA) | [7], [8] | |||
Molecule Alteration | Expression | Up-regulation |
||
Resistant Disease | Bacterial infection [ICD-11: 1A00-1C4Z] | |||
Experimental Note | Identified from the Human Clinical Data | |||
In Vitro Model | Escherichia coli HB101 | 634468 | ||
Escherichia coli JM101 | 562 | |||
Experiment for Molecule Alteration |
Whole genome sequence assay | |||
Mechanism Description | Beta-lactamases (Beta-lactamhydrolase, EC 3.5.2.6), responsible for most of the resistance to Beta-lactam antibiotics, are often plasmid mediated.The OXA-1 beta-lactamase gene is part of Tn2603, which is borne on the R plasmid RGN238. | |||
Key Molecule: Beta-lactamase (BLA) | [9] | |||
Molecule Alteration | Missense mutation | p.V88L+p.M154L |
||
Resistant Disease | Bacterial infection [ICD-11: 1A00-1C4Z] | |||
Experimental Note | Identified from the Human Clinical Data | |||
In Vitro Model | Escherichia coli TOP10 | 83333 | ||
Escherichia coli ST648 | 562 | |||
Experiment for Molecule Alteration |
Whole genome sequence assay; Allelic frequency measurement assay | |||
Experiment for Drug Resistance |
Etest assay | |||
Mechanism Description | NDM-5 differed from existing enzymes due to substitutions at positions 88 (Val - Leu) and 154 (Met - Leu) and reduced the susceptibility of Escherichia coli TOP10 transformants to expanded-spectrum cephalosporins and carbapenems when expressed under its native promoter. |
Malaria [ICD-11: 1F45]
Drug Resistance Data Categorized by Their Corresponding Mechanisms | ||||
Drug Inactivation by Structure Modification (DISM) | ||||
Key Molecule: CAM-1 carbapenemase (CAM1) | [2] | |||
Molecule Alteration | Expression | Up-regulation |
||
Resistant Disease | Pseudomonas infection [ICD-11: 1F45.1] | |||
Experimental Note | Identified from the Human Clinical Data | |||
In Vitro Model | Escherichia coli TOP10 | 83333 | ||
Pseudomonas aeruginosa N17-01167 | 287 | |||
Pseudomonas aeruginosa N17-01173 | 287 | |||
Pseudomonas aeruginosa N17-02436 | 287 | |||
Pseudomonas aeruginosa N17-02437 | 287 | |||
Experiment for Molecule Alteration |
Whole genome sequencing assay | |||
Experiment for Drug Resistance |
Vitek 2 assay; Etest assay | |||
Mechanism Description | A novel class B Beta-lactamase gene, blaCAM-1, exhibited resistance to imipenem, meropenem, doripenem, cefotaxime, ceftazidime, cefoxitin, piperacillin/tazobactam, ceftazidime/avibactam and ceftolozane/tazobactam. |
References
If you find any error in data or bug in web service, please kindly report it to Dr. Sun and Dr. Zhang.